2024
Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers
Allada S, Gupta V, Hofmeister C, Kaufman J, Dhodapkar M, Lonial S, Nooka A, Joseph N. Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers. Blood 2024, 144: 7861. DOI: 10.1182/blood-2024-210996.Peer-Reviewed Original ResearchB-cell maturation antigenRefractory myelomaAnti-BCMABispecific antibodiesInternational Myeloma Working Group Uniform Response CriteriaInstitutional experienceWinship Cancer Institute of Emory UniversityCAR-T cell therapyBispecific T-cell engagerSignificant tumor burdenT-cell engagersDecreased performance statusWinship Cancer InstituteRate of gradeLimited treatment optionsStatistically significant differenceMedian PFSPretreated patientsCAR-TMedian followResponse CriteriaTumor burdenPretreated populationDose reductionMaturation antigen
2023
Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration
Marin E, Scott S, Maples K, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Kaufman J, Lonial S, Nooka A. Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration. Blood 2023, 142: 2008. DOI: 10.1182/blood-2023-189878.Peer-Reviewed Original ResearchCytokine release syndromeGrade 3 cytokine release syndromeSeverity of CRSB-cell maturation antigenProphylactic cohortRelease syndromeMedian durationRRMM patientsAdditional patientsREMS programT-cell engaging therapiesGrade 1Institutional guidelinesDose of steroidsFirst full doseDays of dischargeEmory University HospitalCD38 monoclonal antibodyUsage of steroidsCellular Therapy criteriaDose delaysNeurotoxicity syndromeOutpatient administrationT cell surfaceTocilizumab group